Clovis Oncology (CLVS) jumps as new drug OK'd

Clovis Oncology, Inc.

gained 9.2% to $74.96 as the company reported that it has received breakthrough therapy designation for Rucaparib for monotherapy treatment of advanced ovarian cancer. Share volume was 835,000, compared to an all-day average of 524,000